In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 Christie Ballantyne
Speaker
Christie Ballantyne
Christie Ballantyne Christie Ballantyne

Baylor College of Medicine, Houston (United States of America)

Dr Ballantyne is the Chief of Cardiology and Cardiovascular Reserach at Baylor College of Medicine, a Professor in the Departments of Medicine, Genetics and Physiology, and hold the J.S. Abercrombie Chair for Atherosclerosis Research. His major career focus has been in the area of preventive cardiology with research interests in lipoproteins, atherosclerosis, inflammation, biomarkers and genetics in both clinican and basic research.

27 presentations from this speaker

A transatlantic discussion on the new LDL-c guidelines - What are the key differences?

Event : ESC Congress 2019

  • Session : LDL-c guidance on the novel ESC/EAS dyslipidaemia guidelines: expert discussions on practical implications
  • Speaker : C Ballantyne (Houston,US)
  • Organised by PACE-CME, supported with educational grants provided by Amgen, Pfizer and Sanofi-Regeneron

Clinical trial updates

Event : ESC Congress 2019

  • Session : Targeting of PCSK9 with siRNA for LDL-C reduction in a high-risk population
  • Speaker : C Ballantyne (Houston,US)
  • Sponsored by National Lipid Association

Conclusion and key takeaways

Event : ESC Congress 2019

  • Session : Evolving scientific evidence with PCSK9 inhibitors based on ODYSSEY outcomes
  • Speaker : JW Jukema (Leiden,NL), F Schiele (Besancon,FR), C Ballantyne (Houston,US)
  • Sponsored by Sanofi and Regeneron

Evaluating the benefit/risk and safety profile of PCSK9 inhibitors - Clinical and economic implications

Event : ESC Congress 2019

  • Session : Evolving scientific evidence with PCSK9 inhibitors based on ODYSSEY outcomes
  • Speaker : C Ballantyne (Houston,US)
  • Sponsored by Sanofi and Regeneron

Panel discussion

Event : ESC Congress 2019

  • Session : Evolving scientific evidence with PCSK9 inhibitors based on ODYSSEY outcomes
  • Speaker : JW Jukema (Leiden,NL), F Schiele (Besancon,FR), C Ballantyne (Houston,US)
  • Sponsored by Sanofi and Regeneron

Safety profile of bempedoic acid: pooled analysis of 4 phase 3 clinical trials

Event : ESC Congress 2019

  • Session : Lipid management and outcome
  • Speaker : C Ballantyne (Houston,US)

LDL-cholesterol and secondary prevention of atherosclerotic disease – when less is definitely more!

Event : ESC Congress 2018

  • Session : LDL-cholesterol and secondary prevention of atherosclerotic disease - When less is definitely more!
  • Speaker : C Ballantyne (Houston,US), KK Ray (London,GB)
  • Sponsored by Amgen Europe GmbH

Panel discussion and wrap-up - LDL-cholesterol and secondary prevention of atherosclerotic disease - When less is definitely more!

Event : ESC Congress 2018

  • Session : LDL-cholesterol and secondary prevention of atherosclerotic disease - When less is definitely more!
  • Speaker : U Landmesser (Berlin,DE), C Ballantyne (Houston,US), KK Ray (London,GB)
  • Sponsored by Amgen Europe GmbH

Where PCSK9 inhibitors can make a difference

Event : ESC Congress 2018

  • Session : LDL-cholesterol and secondary prevention of atherosclerotic disease - When less is definitely more!
  • Speaker : C Ballantyne (Houston,US)
  • Sponsored by Amgen Europe GmbH

Successes and challenges in clinical practice.

Event : ESC Congress 2017

  • Session : State-of-the-art lipid treatment in coronary patients in 2017
  • Speaker : C Ballantyne (Houston,US)
  • Sponsored by MSD

Aggressive LDL-C lowering to impact plaque burden: what is the evidence demonstrating?

Event : ESC Congress 2016

  • Session : The state of the science of LDL-C lowering in patients with coronary atherosclerosis
  • Speaker : C Ballantyne (Houston,US), D Bhatt (Newton,US), SJ Nicholls (Adelaide,AU)
  • Sponsored by PeerVoice

Evaluating the relationship between plaque burden and CV events in coronary atherosclerosis.

Event : ESC Congress 2016

  • Session : The state of the science of LDL-C lowering in patients with coronary atherosclerosis
  • Speaker : SJ Nicholls (Adelaide,AU), C Ballantyne (Houston,US), D Bhatt (Newton,US)
  • Sponsored by PeerVoice

Optimizing treatment for patients with coronary atherosclerosis: translating the evidence into practical strategies.

Event : ESC Congress 2016

  • Session : The state of the science of LDL-C lowering in patients with coronary atherosclerosis
  • Speaker : D Bhatt (Newton,US), C Ballantyne (Houston,US), SJ Nicholls (Adelaide,AU)
  • Sponsored by PeerVoice

Q&A: managing coronary atherosclerosis in practice.

Event : ESC Congress 2016

  • Session : The state of the science of LDL-C lowering in patients with coronary atherosclerosis
  • Speaker : C Ballantyne (Houston,US), D Bhatt (Newton,US), SJ Nicholls (Adelaide,AU)
  • Sponsored by PeerVoice

Current unmet needs and evidence-based approaches for Cardiovascular risk reduction among high-risk patients.

Event : ESC Congress 2015

  • Session : PCSK9 inhibitors and evidence-based outcomes - What does the future hold?
  • Speaker : C Ballantyne (Houston,US)
  • Sponsored by Pfizer

Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on apolipoprotein C-III in patients from the MARINE and ANCHOR studies

Event : ESC Congress 2015

  • Session : Treatment strategies and adherence: can we decrease risk?
  • Speaker : C Ballantyne (Houston,US)

Introduction - Targeting the high-risk patient: evolving concepts on optimally modifying risk by lipid-modulating therapies.

Event : ESC Congress 2015

  • Session : Targeting the high-risk patient: evolving concepts on optimally modifying risk by lipid-modulating therapies
  • Speaker : C Ballantyne (Houston,US)
  • Organised by Leiden University Medical Center Course Director: Wouter Jukema Supported by an unrestricted educational grant from AstraZeneca

Panel discussion and Q&A - PCSK9 inhibitors and evidence-based outcomes - What does the future hold?

Event : ESC Congress 2015

  • Session : PCSK9 inhibitors and evidence-based outcomes - What does the future hold?
  • Speaker : P Barter (Randwick,AU), C Ballantyne (Houston,US)
  • Sponsored by Pfizer

Summary and close - Targeting the high-risk patient: evolving concepts on optimally modifying risk by lipid-modulating therapies.

Event : ESC Congress 2015

  • Session : Targeting the high-risk patient: evolving concepts on optimally modifying risk by lipid-modulating therapies
  • Speaker : C Ballantyne (Houston,US)
  • Organised by Leiden University Medical Center Course Director: Wouter Jukema Supported by an unrestricted educational grant from AstraZeneca

A new approach to statin treatment: lipid lowering therapy guidelines in the US.

Event : ESC Congress 2014

  • Session : Comparing the European and US (ACC/AHA) lipid lowering therapy guidelines: the good, the bad and the uncertain
  • Speaker : C Ballantyne (Houston,US)
  • Organised by University Hospital, Umea / Course Director: Ulf Naeslund / Supported by an unrestricted educational grant from AstraZeneca

Current controversies in lipid management and guidelines - a patient oriented approach.

Event : ESC Congress 2014

  • Session : Current controversies in lipid management and guidelines - a patient oriented approach
  • Speaker : C Ballantyne (Houston,US)
  • Sponsored by MSD

LDL-C as a therapeutic target and supporting evidence.

Event : ESC Congress 2014

  • Session : LDL-C & cardiovascular disease - What are the critical questions and what is the evidence?
  • Speaker : C Ballantyne (Houston,US)
  • Sponsored by MSD

PCSK9 inhibitors findings to date: hope on the horizon?

Event : ESC Congress 2014

  • Session : The future of lipid management: novel approaches for the at-risk patient
  • Speaker : C Ballantyne (Houston,US)
  • Sponsored by Cleveland Clinic

Conclusion: changing paradigms in lipid drug discovery.

Event : ESC Congress 2013

  • Session : Changing paradigms in lipid drug discovery: the emerging role of genomics and biotechnology
  • Speaker : C Ballantyne (Houston,US)
  • Sponsored by Sanofi and Regeneron

Future hopes and expectations to prevent cardiovascular disease.

Event : ESC Congress 2013

  • Session : Targeting dyslipidaemia and cardiovascular disease prevention: a life-long campaign
  • Speaker : C Ballantyne (Houston,US)
  • Organised by University Hospital, Umea / Course Director: Prof. Ulf Naeslund / Supported by an unrestricted educational grant from AstraZeneca

Panel discussion: changing paradigms in lipid drug discovery.

Event : ESC Congress 2013

  • Session : Changing paradigms in lipid drug discovery: the emerging role of genomics and biotechnology
  • Speaker : C Ballantyne (Houston,US), GK Hovingh (Amsterdam,NL), A Catapano (Milan,IT)
  • Sponsored by Sanofi and Regeneron

Welcome and introduction: changing paradigms in lipid drug discovery.

Event : ESC Congress 2013

  • Session : Changing paradigms in lipid drug discovery: the emerging role of genomics and biotechnology
  • Speaker : C Ballantyne (Houston,US)
  • Sponsored by Sanofi and Regeneron

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are